ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
간암 치료제 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년까지 12.4%의 CAGR로 42억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 임상시험에 대한 투자 증가, 정밀 의료 채택 증가, 세계 의약품 승인 급증, 간염 유병률 증가, 연구 및 기술 혁신의 확대에 기인합니다. 예측 기간 동안 예상되는 주요 동향으로는 표적치료의 발전, 면역치료의 발전, 맞춤의료의 발전, 종양학에서의 인공지능의 통합, 바이오마커 진단의 도입 등이 있습니다.
연구개발에 대한 투자 확대는 간암 치료제 시장의 확대를 촉진할 것으로 예상됩니다. 연구개발은 지식을 향상시키고 시장에 혁신적인 솔루션을 제공하기 위해 신제품, 신기술 또는 기술을 조사, 설계 및 평가하는 체계적인 프로세스를 포함합니다. 연구개발의 증가는 업계 전반의 혁신과 기술 진보에 대한 수요 증가가 원동력이 되고 있으며, 기업들은 경쟁력을 유지하기 위해 신제품을 개발하거나 기존 제품을 개선하기 위해 노력하고 있습니다. 간암 치료제의 경우, 연구 개발은 건강한 간 조직에 대한 피해를 최소화하면서 치료 효과를 높이는 표적 치료제의 발견을 지원합니다. 예를 들어, 2024년 9월 영국에 본사를 둔 암 연구 기관인 Cancer Research UK는 2023/24 회계연도 동안 암 연구에 5억 3,300만 달러(3억 9,900만 파운드)를 투자하고, 1억 2,400만 달러(9,300만 파운드)를 모든 암종 관련 연구에 할당할 예정입니다. 모든 암종과 관련된 연구에 1억 1,200만 달러(8,400만 파운드)를 기초 생물학적 연구에 투자할 것이라고 보고했습니다. 따라서 연구개발 활동의 증가는 간암 치료제 시장의 성장에 기여하고 있습니다.
간암 치료제 시장의 주요 기업들은 치료의 정확성과 환자 예후를 개선하기 위해 첨단 치료법을 포함한 혁신적인 치료법 개발에 우선순위를 두고 있습니다. 첨단 간암 치료에는 면역치료, 표적치료, 유전자 치료, CAR-T 세포 치료, TACE 및 절제술과 같은 최소침습적 기술과 같은 새로운 접근법이 포함되며, 간암 치료의 효과와 정확성을 향상시키는 것을 목표로 하고 있습니다. 예를 들어, 인도의 의료기기 제조업체인 Telmo India는 2023년 11월 인도에서 간암에 대한 첨단 풍선 TACE 치료를 시작했습니다. 이 장비는 건강한 조직 손상을 줄이고 간 기능을 유지하면서 간 종양에 직접 화학요법을 투여함으로써 경동맥화학색전술(TACE)의 정확성과 효율성을 높이기 위해 고안된 것으로, 특히 인도에서 가장 발병률이 높은 간암인 간세포암을 대상으로 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 거시경제 시나리오 : 금리·인플레이션·지정학·무역 전쟁·관세·코로나와 회복이 시장에 미치는 영향을 포함한다
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 간암 치료제 시장 : PESTEL 분석(정치·사회·기술·환경·법적 요인, 촉진요인, 억제요인)
최종 이용 산업 분석
세계의 간암 치료제 시장 : 성장률 분석
세계의 간암 치료제 시장 규모·성장률 : 실적치, 2019-2024년
세계의 간암 치료제 시장 규모·성장률 : 예측치, 2024-2029년, 2034년
세계의 간암 치료제 시장 : 총유효과 시장(TAM)
제6장 시장 세분화
세계의 간암 치료제 시장 : 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
간세포암
담관암
간아종
기타 종류
세계의 간암 치료제 시장 : 치료법별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
표적요법
면역요법
화학요법
기타 치료법
세계의 간암 치료제 시장 : 투여 경로별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
경구제
주사제
세계의 간암 치료제 시장 : 유통 채널별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
세계의 간암 치료제 시장 : 간세포암 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
표적요법
면역요법
화학요법
병용요법
세계의 간암 치료제 시장 : 담관암 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
표적요법
화학요법
면역요법
광역학 요법
세계의 간암 치료제 시장 : 간아종 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
화학요법
표적요법
면역요법
외과용 보조제
세계의 간암 치료제 시장 : 기타 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
화학요법
표적요법
실험적 또는 적응외 치료법
지지요법제
제7장 지역별·국가별 분석
세계의 간암 치료제 시장 : 지역별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
세계의 간암 치료제 시장 : 국가별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
간암 치료제 시장 : 경쟁 구도
간암 치료제 시장 : 기업 개요
Pfizer Inc.(개요, 제품 및 서비스, 전략, 재무 분석)
F. Hoffmann-La Roche Ltd(개요, 제품 및 서비스, 전략, 재무 분석)
Merck & Co. Inc.(개요, 제품 및 서비스, 전략, 재무 분석)
AstraZeneca plc(개요, 제품 및 서비스, 전략, 재무 분석)
Bayer AG(개요, 제품 및 서비스, 전략, 재무 분석)
제31장 기타 주요 기업과 혁신적 기업
Bristol-Myers Squibb Company
Eli Lilly and Company
Novartis AG
Takeda Pharmaceutical Company Limited
Hetero Drugs Limited
Sun pharma
Eisai Company Limited
Genentech Incorporated
Ipsen Societe Anonyme
Cipla Limited
Dr. Reddy's Laboratories Limited
BeiGene Ltd.
Exelixis Incorporated
Natco Pharma Limited
MacroGenics Inc.
제32장 세계 시장 : 경쟁 벤치마킹·대시보드
제33장 주요 기업 인수합병(M&A)
제34장 최근의 시장 동향
제35장 시장 잠재력 높은 나라·부문과 전략
간암 치료제 시장 : 최신 기회를 제공하는 국가(2029년)
간암 치료제 시장 : 최신 기회를 제공하는 부문(2029년)
간암 치료제 시장 : 성장 전략(2029년)
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Liver cancer drugs are a category of pharmaceutical substances formulated to address the growth of malignant cells in a critical organ responsible for detoxification, metabolism, and nutrient storage. These medications function by interfering with the biological processes that support the proliferation, division, and immune evasion of abnormal cells.
The primary categories of liver cancer drugs include treatments for hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and others. Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, indicating it originates within the liver rather than metastasizing from another organ. Treatment options encompass targeted therapy, immunotherapy, chemotherapy, and others, which may be administered orally or via injection. These drugs are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online platforms.
The liver cancer drugs market research report is one of a series of new reports from The Business Research Company that provides liver cancer drugs market statistics, including liver cancer drugs industry global market size, regional shares, competitors with a liver cancer drugs market share, detailed liver cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer drugs industry. This liver cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The liver cancer drug market size has grown rapidly in recent years. It will grow from $2.34 billion in 2024 to $2.64 billion in 2025 at a compound annual growth rate (CAGR) of 12.7%. The growth observed during the historic period can be credited to the rising incidence of liver cancer, an increasing aging population, expanding global healthcare expenditure, heightened awareness and screening efforts, and a growing demand for immunotherapy.
The liver cancer drug market size is expected to see rapid growth in the next few years. It will grow to $4.22 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The anticipated growth in the forecast period can be attributed to increased investments in clinical trials, a rising adoption of precision medicine, a surge in global drug approvals, a growing prevalence of hepatitis, and expanding research and innovation. Key trends expected during the forecast period include progress in targeted therapies, advancements in immunotherapy treatments, developments in personalized medicine, the integration of artificial intelligence in oncology, and the incorporation of biomarker diagnostics.
The growing investment in research and development is expected to drive the expansion of the liver cancer drug market. Research and development involve a systematic process of investigating, designing, and assessing new products, technologies, or techniques to enhance knowledge and deliver innovative solutions to the market. The increase in research and development is driven by a rising demand for innovation and technological progress across industries, prompting companies to develop new products and improve existing ones to remain competitive. In the context of liver cancer drugs, research and development support the discovery of targeted therapies that enhance treatment efficacy while minimizing harm to healthy liver tissue. For example, in September 2024, Cancer Research UK, a UK-based cancer research organization, reported an investment of $533 million (£399 million) in cancer research during the 2023/24 financial year, with $124 million (£93 million) allocated to research relevant to all cancer types and $112 million (£84 million) directed to fundamental biological studies. Therefore, the increase in research and development activities is contributing to the growth of the liver cancer drug market.
Key players in the liver cancer drug market are prioritizing the development of innovative treatments, including advanced therapies, to improve treatment accuracy and patient outcomes. Advanced liver cancer therapies encompass novel approaches such as immunotherapy, targeted therapy, gene therapy, CAR-T cell therapy, and minimally invasive techniques such as TACE and ablation, which aim to increase the effectiveness and precision of liver cancer treatment. For instance, in November 2023, Terumo India, an India-based medical device manufacturer, launched advanced Balloon-TACE therapy for liver cancer in India, featuring two innovative devices, Occlusafe and LifePearl. These devices are designed to enhance the accuracy and efficiency of transcatheter arterial chemoembolization (TACE) by delivering chemotherapy directly to liver tumors while limiting damage to healthy tissue and maintaining liver function, specifically targeting hepatocellular carcinoma, the most prevalent form of liver cancer in India.
In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical firm, completed the acquisition of Surface Oncology Inc. for an undisclosed amount. Through this acquisition, Coherus expanded its immuno-oncology pipeline to include several antibody-based immunotherapy candidates. These treatments are intended to enhance both innate and adaptive immune system responses, ultimately improving therapeutic outcomes for cancer patients. Surface Oncology Inc. is a US-based company specializing in the development of liver cancer drugs.
Major players in the liver cancer drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Takeda Pharmaceutical Company Limited, Hetero Drugs Limited, Sun pharma, Eisai Company Limited, Genentech Incorporated, Ipsen Societe Anonyme, Cipla Limited, Dr. Reddy's Laboratories Limited, BeiGene Ltd., Exelixis Incorporated, Natco Pharma Limited, and MacroGenics Inc.
North America was the largest region in the liver cancer drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in liver cancer drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the liver cancer drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The liver cancer drug market consists of revenues earned by entities by providing services such as clinical trial management, pharmacovigilance services, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer drug market also includes sales of monoclonal antibodies, hormonal therapy drugs, gene therapy products, and liver-specific drug delivery systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Liver Cancer Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on liver cancer drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for liver cancer drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liver cancer drug market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Hepatocellular Carcinoma; Cholangio Carcinoma; Hepatoblastoma; Other Types
2) By Therapy: Targeted Therapy; Immunotherapy; Chemotherapy; Other Therapies
3) By Route Of Administration: Oral; Injectable
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Hepatocellular Carcinoma: Targeted Therapy; Immunotherapy; Chemotherapy; Combination Therapy
2) By Cholangio Carcinoma: Targeted Therapy; Chemotherapy; Immunotherapy; Photodynamic Therapy
3) By Hepatoblastoma: Chemotherapy; Targeted Therapy; Immunotherapy; Surgical Adjuvants
4) By Other Types: Chemotherapy; Targeted Therapy; Experimental Or Off-label Therapies; Supportive Care Medications
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AstraZeneca plc; Bayer AG
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Liver Cancer Drug Market Characteristics
3. Liver Cancer Drug Market Trends And Strategies
4. Liver Cancer Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Liver Cancer Drug Growth Analysis And Strategic Analysis Framework
5.1. Global Liver Cancer Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Liver Cancer Drug Market Growth Rate Analysis
5.4. Global Liver Cancer Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Liver Cancer Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Liver Cancer Drug Total Addressable Market (TAM)
6. Liver Cancer Drug Market Segmentation
6.1. Global Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types
6.2. Global Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapy
Immunotherapy
Chemotherapy
Other Therapies
6.3. Global Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
6.4. Global Liver Cancer Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Liver Cancer Drug Market, Sub-Segmentation Of Hepatocellular Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapy
Immunotherapy
Chemotherapy
Combination Therapy
6.6. Global Liver Cancer Drug Market, Sub-Segmentation Of Cholangio Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapy
Chemotherapy
Immunotherapy
Photodynamic Therapy
6.7. Global Liver Cancer Drug Market, Sub-Segmentation Of Hepatoblastoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Targeted Therapy
Immunotherapy
Surgical Adjuvants
6.8. Global Liver Cancer Drug Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Targeted Therapy
Experimental Or Off-label Therapies
Supportive Care Medications
7. Liver Cancer Drug Market Regional And Country Analysis
7.1. Global Liver Cancer Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Liver Cancer Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Liver Cancer Drug Market
8.1. Asia-Pacific Liver Cancer Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Liver Cancer Drug Market
9.1. China Liver Cancer Drug Market Overview
9.2. China Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Liver Cancer Drug Market
10.1. India Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Liver Cancer Drug Market
11.1. Japan Liver Cancer Drug Market Overview
11.2. Japan Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Liver Cancer Drug Market
12.1. Australia Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Liver Cancer Drug Market
13.1. Indonesia Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Liver Cancer Drug Market
14.1. South Korea Liver Cancer Drug Market Overview
14.2. South Korea Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Liver Cancer Drug Market
15.1. Western Europe Liver Cancer Drug Market Overview
15.2. Western Europe Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Liver Cancer Drug Market
16.1. UK Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Liver Cancer Drug Market
17.1. Germany Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Liver Cancer Drug Market
18.1. France Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Liver Cancer Drug Market
19.1. Italy Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Liver Cancer Drug Market
20.1. Spain Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Liver Cancer Drug Market
21.1. Eastern Europe Liver Cancer Drug Market Overview
21.2. Eastern Europe Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Liver Cancer Drug Market
22.1. Russia Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Liver Cancer Drug Market
23.1. North America Liver Cancer Drug Market Overview
23.2. North America Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Liver Cancer Drug Market
24.1. USA Liver Cancer Drug Market Overview
24.2. USA Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Liver Cancer Drug Market
25.1. Canada Liver Cancer Drug Market Overview
25.2. Canada Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Liver Cancer Drug Market
26.1. South America Liver Cancer Drug Market Overview
26.2. South America Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Liver Cancer Drug Market
27.1. Brazil Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Liver Cancer Drug Market
28.1. Middle East Liver Cancer Drug Market Overview
28.2. Middle East Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Liver Cancer Drug Market
29.1. Africa Liver Cancer Drug Market Overview
29.2. Africa Liver Cancer Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Liver Cancer Drug Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Liver Cancer Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Liver Cancer Drug Market Competitive Landscape And Company Profiles
30.1. Liver Cancer Drug Market Competitive Landscape
30.2. Liver Cancer Drug Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Liver Cancer Drug Market Other Major And Innovative Companies
31.1. Bristol-Myers Squibb Company
31.2. Eli Lilly and Company
31.3. Novartis AG
31.4. Takeda Pharmaceutical Company Limited
31.5. Hetero Drugs Limited
31.6. Sun pharma
31.7. Eisai Company Limited
31.8. Genentech Incorporated
31.9. Ipsen Societe Anonyme
31.10. Cipla Limited
31.11. Dr. Reddy's Laboratories Limited
31.12. BeiGene Ltd.
31.13. Exelixis Incorporated
31.14. Natco Pharma Limited
31.15. MacroGenics Inc.
32. Global Liver Cancer Drug Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Liver Cancer Drug Market
34. Recent Developments In The Liver Cancer Drug Market
35. Liver Cancer Drug Market High Potential Countries, Segments and Strategies
35.1 Liver Cancer Drug Market In 2029 - Countries Offering Most New Opportunities
35.2 Liver Cancer Drug Market In 2029 - Segments Offering Most New Opportunities
35.3 Liver Cancer Drug Market In 2029 - Growth Strategies
